ARCHIVES

2025 ISSUES

VOL. 1, ISSUE 1 (2025)

Comparative study of Rivina humilis and standard lipid-lowering drugs in high-fat diet-fed rats

Authors

Shwetha S

Abstract

Hyperlipidemia and obesity are major risk factors for cardiovascular diseases and metabolic disorders worldwide. Rivina humilis L., a medicinal plant traditionally used for its therapeutic properties, has recently gained attention for its potential lipid-lowering effects. This study aimed to conduct a comparative evaluation of the hypolipidemic effects of Rivina humilis extract and a standard lipid-lowering drug (atorvastatin) in high-fat diet (HFD)-induced hyperlipidemic Wistar rats. Rats were divided into five groups: normal control, HFD control, HFD + low-dose Rivina humilis, HFD + high-dose Rivina humilis, and HFD + atorvastatin. Treatments were administered orally for 28 days, and serum lipid parameters, including total cholesterol, triglycerides, low-density lipoprotein (LDL), and high-density lipoprotein (HDL), were measured. Histopathological analysis of liver tissues was also performed to assess hepatic lipid accumulation.

Results demonstrated that Rivina humilis significantly reduced serum total cholesterol, triglycerides, and LDL levels while increasing HDL in a dose-dependent manner, with the high-dose extract exhibiting effects comparable to atorvastatin. Liver histology confirmed attenuation of hepatic steatosis in treated groups. No signs of toxicity were observed in any treatment group. These findings suggest that Rivina humilis possesses promising hypolipidemic and hepatoprotective properties, comparable to standard pharmacological therapy. The study provides a scientific basis for the traditional use of Rivina humilis in managing hyperlipidemia and highlights its potential as a natural alternative or adjunct to conventional lipid-lowering drugs.

Download

Pages:1-4

How to cite this article:

Shwetha S "Comparative study of <i>Rivina humilis</i> and standard lipid-lowering drugs in high-fat diet-fed rats". World Journal of Pharma, Vol 1, Issue 1, 2025, Pages 1-4

Download Author Certificate

Please enter the email address corresponding to this article submission to download your certificate.